Tumor biomarkers, such as CEA, CA125, NSE, CYFRA21-1, and p53, are currently used in cancer diagnosis and prognosis, but few of them are ideal for NSCLC because of low sensitivity and specificity (23–25). The gene discussed is ENO2; the disease is cancer.